These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30146790)

  • 21. Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
    Kurozumi A; Okada Y; Sugai K; Torimoto K; Tanaka Y
    J UOEH; 2018; 40(1):1-9. PubMed ID: 29553070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
    Sha S; Devineni D; Ghosh A; Polidori D; Hompesch M; Arnolds S; Morrow L; Spitzer H; Demarest K; Rothenberg P
    PLoS One; 2014; 9(9):e110069. PubMed ID: 25268802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
    Takamiya Y; Okamura K; Shirai K; Okuda T; Kobayashi K; Urata H
    Clin Exp Hypertens; 2020; 42(3):197-204. PubMed ID: 30974980
    [No Abstract]   [Full Text] [Related]  

  • 25. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
    Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
    Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Yamada Y
    Adv Ther; 2020 May; 37(5):2477-2492. PubMed ID: 32323194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of efficacy between dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor on metabolic risk factors in Japanese patients with type 2 diabetes mellitus: Results from the CANTABILE study.
    Son C; Makino H; Kasahara M; Tanaka T; Nishimura K; Taneda S; Nishimura T; Kasama S; Ogawa Y; Miyamoto Y; Hosoda K
    Diabetes Res Clin Pract; 2021 Oct; 180():109037. PubMed ID: 34481910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ketoconazole on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor teneligliptin: an open-label study in healthy white subjects in Germany.
    Nakamaru Y; Hayashi Y; Sekine M; Kinoshita S; Thompson J; Kawaguchi A; Davies M; Jürgen Heuer H; Yamazaki H; Akimoto K
    Clin Ther; 2014 May; 36(5):760-9. PubMed ID: 24726088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.
    Aso Y; Kase M; Sagara M; Sakurai S; Iijima T; Tomaru T; Jojima T; Usui I
    Am J Med Sci; 2020 Sep; 360(3):261-267. PubMed ID: 32540146
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
    Scheen AJ
    Clin Pharmacokinet; 2017 Jul; 56(7):703-718. PubMed ID: 28039605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.
    Homma K; Yoshizawa J; Shiina Y; Ozawa H; Igarashi M; Matsuoka T; Sasaki J; Yoshizawa M; Homma Y
    Drugs R D; 2017 Sep; 17(3):397-402. PubMed ID: 28577292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined treatment with teneligliptin and canagliflozin additively suppresses high-fat diet-induced body weight gain in mice with modulation of lipid metabolism-related gene expression.
    Kawarasaki S; Sawazaki H; Iijima H; Takahashi H; Nomura W; Inoue K; Kawada T; Goto T
    Eur J Pharmacol; 2023 May; 947():175682. PubMed ID: 36965744
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.
    Takebayashi K; Hara K; Terasawa T; Naruse R; Suetsugu M; Tsuchiya T; Inukai T
    Endocr J; 2017 Sep; 64(9):923-931. PubMed ID: 28824041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
    Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
    Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Teneligliptin for the treatment of type 2 diabetes.
    Goda M; Kadowaki T
    Drugs Today (Barc); 2013 Oct; 49(10):615-29. PubMed ID: 24191255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan.
    Kadowaki T; Haneda M; Ito H; Sasaki K; Matsukawa M; Yamada Y
    Adv Ther; 2020 Mar; 37(3):1065-1086. PubMed ID: 31873865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Affecting Canagliflozin-Induced Transient Urine Volume Increase in Patients with Type 2 Diabetes Mellitus.
    Tanaka H; Takano K; Iijima H; Kubo H; Maruyama N; Hashimoto T; Arakawa K; Togo M; Inagaki N; Kaku K
    Adv Ther; 2017 Feb; 34(2):436-451. PubMed ID: 27981497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
    Kitada M; Ogura Y; Nitta K; Fujii M; Kanasaki K; Konishi K; Iida Y; Nakagawa A; Koya D
    J Diabetes Investig; 2019 May; 10(3):706-713. PubMed ID: 30136384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diuretic and Natriuretic Effects of Dipeptidyl Peptidase-4 Inhibitor Teneligliptin: The Contribution of Glucagon-like Peptide-1.
    Moroi M; Kubota T
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):159-64. PubMed ID: 25853991
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management.
    van Baar MJB; van Ruiten CC; Muskiet MHA; van Bloemendaal L; IJzerman RG; van Raalte DH
    Diabetes Care; 2018 Aug; 41(8):1543-1556. PubMed ID: 30030256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.